MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: A randomised placebo-controlled trial

Lancet

Volumn 360, Issue 9326, 2002, Pages 7-22

  Collins, Rory ^a   Armitage, Jane ^a   Parish, Sarah ^a   Sleight, Peter ^a   Peto, Richard ^a  

^a RADCLIFFE INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; SIMVASTATIN;

ADULT; AGED; ARTICLE; CANCER; CARDIOMYOPATHY; CARDIOVASCULAR RISK; CAUSE OF DEATH; CEREBROVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG USE; FEMALE; HEART INFARCTION; HEART PROTECTION; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PATIENT COMPLIANCE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; STROKE;

EID: 0037031061     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(02)09327-3     Document Type: Article

References (56)

1. For participants in the conference on low cholesterol:mortality associations. Report of the conference on low blood cholesterol:mortality associations
2. Diabetes, other risk factors and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial
3. Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations
4. Serum cholesterol, other risk factors, and cardiovascular disease in a Japanese cohort
5. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian simvastatin survival study (4S)
6. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
7. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
8. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts
9. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
10. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS
11. Need for large scale randomised evidence about lowering LDL cholesterol in people with diabetes mellitus: MRC/BHF heart protection study and other major trials
12. Age and gender bias in statin trials
13. Low-density-lipoprotein cholesterol goals for patients with coronary disease: Treating between the lines
14. Clinical reality of coronary prevention guidelines: A comparison of EUROASPIRE I and II in nine countries
15. Lowering cholesterol concentrations and mortality: A quantitative review of primary prevention trials
16. Might treatment of hypercholesterolaemia increase non-cardiac mortality?
17. Should there be a moratorium on the use of cholesterol lowering drugs?
18. Carcinogenicity of lipid-lowering drugs
19. Cholesterol reduction and non-illness mortality: Meta-analysis of randomised clinical trials
20. Total cholesterol and risk of mortality in the oldest old
21. Cholesterol and all-cause mortality in elderly people from the Honolulu Heart Program: A cohort study
22. MRC/BHF Heart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: Early safety and efficacy experience
23. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20 536 high-risk individuals: A randomised placebo-controlled trial
24. And the ETDRS Research Group. C-peptide and the classification of diabetes mellitus patients in the early treatment diabetic retinopathy study: Report number 6
25. Estimating the effect of the run-in on the power of the Physicians' Health Study
26. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge
27. Immunoseparation method for measuring low-density lipoprotein cholesterol directly from serum evaluated
28. Comparison of an immunoprecipitation method for direct measurement of LDL cholesterol with beta-quantification (ultracentrifugation)
29. Allocation of patients to treatment groups in a controlled clinical study
30. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II Analysis and examples
31. Reliable assessment of the effects of treatment on mortality and major morbidity, I: Clinical trials
32. Cholesterol and total mortality: Need for larger trials
33. Protocol for a prospective collaborative overview of all current and planned randomized trials of cholesterol treatment regimens
34. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease
35. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS)
36. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial
37. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S)
38. Midlife vascular risk factors and Alzheimer's disease in later life: Longitudinal, population based study
39. Statins and the risk of dementia
40. Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people
41. The development and initial validation of a telephone-administered cognitive test battery (TACT)
42. Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women
43. Statin use, bone mineral density, and fracture risk: Geelong Osteoporosis Study
44. Effect of pravastatin on frequency of fracture in the LIPID study: Secondary analysis of a randomised controlled trial
45. Reduction of stroke events with pravastatin: The Prospective Pravastatin Pooling (PPP) Project
46. Statins for stroke prevention?
47. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: The Prospective Pravastatin Pooling Project
48. Cerivastatin and reports of fatal rhabdomylosis
49. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
50. Prevention of coronary heart disease in clinical practice: Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention
51. Stroke incidence, case fatality, and mortality in the WHO MONICA Project
52. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients
53. Beta blockade during and after myocardial infarction: An overview of the randomized trials
54. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients
55. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: Results of prospectively designed overviews of randomised trials